威罗菲尼
化学
黑色素瘤
细胞毒性
癌症研究
姜黄素
药理学
特拉尼司特
体外
医学
生物化学
转移性黑色素瘤
作者
Yige Fu,Aishwarya L. Saraswat,Zeng-Hui Wei,Manas Yogendra Agrawal,Vikas V. Dukhande,Sandra E. Reznik,Ketan R. Patel
出处
期刊:Pharmaceutics
[Multidisciplinary Digital Publishing Institute]
日期:2021-07-01
卷期号:13 (7): 1005-1005
被引量:62
标识
DOI:10.3390/pharmaceutics13071005
摘要
A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a synergistic cytotoxic ratio. Both the molecules have extremely poor aqueous solubility. A modified hydration method with citric acid was used to improve the loading of both the molecules in liposomes. ARNIPL with mean particle size 111.1 ± 6.55 nm exhibited more than 90% encapsulation efficiency for both the drugs and was found to be physically stable for a month at 4 °C. Both the molecules and ARNIPL showed significantly higher cytotoxicity, apoptosis and down-regulation of target proteins BRD4 and c-Myc in vemurafenib-resistant cell line (A375R). Vasculogenic mimicry and clonogenic potential of A375R were significantly inhibited by ARNIPL. Tumor growth inhibition in 3D spheroids with reduction of TGF-β1 was observed with ARNIPL treatment. Therefore, ARNIPL could be a promising therapeutic approach for the treatment of vemurafenib-resistant melanoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI